Maharashtra, India

Kriti Ray Bimalendu


Average Co-Inventor Count = 3.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2012

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Innovator Kriti Ray Bimalendu: Pioneering Cancer Therapy

Introduction

Kriti Ray Bimalendu is an accomplished inventor based in Maharashtra, India. She has made significant contributions to the field of cancer therapy through her innovative research and development efforts. Her work focuses on utilizing advanced genetic techniques to combat cancer effectively.

Latest Patents

Kriti holds a patent for her invention titled "RNAi mediated knockdown of NuMA for cancer therapy." This groundbreaking invention involves the use of short interfering nucleic acid molecules (siRNA) to inhibit the expression of the Nuclear Mitotic Apparatus Protein (NuMA) gene. The application of this technology has the potential to revolutionize treatment options for various diseases, including cancer.

Career Highlights

Kriti Ray Bimalendu is currently employed at Reliance Life Sciences Pvt. Ltd., where she continues to advance her research in the field of biotechnology. Her dedication to innovation and her expertise in genetic engineering have positioned her as a key player in the development of novel therapeutic strategies.

Collaborations

Throughout her career, Kriti has collaborated with notable colleagues, including Murali Krishna Addepalli and Gopavaram Vidyadhar Eswar Chandra Reddy. These partnerships have fostered a collaborative environment that enhances the potential for groundbreaking discoveries in cancer treatment.

Conclusion

Kriti Ray Bimalendu's contributions to cancer therapy through her innovative patent and her work at Reliance Life Sciences Pvt. Ltd. highlight her commitment to advancing medical science. Her research not only showcases her expertise but also offers hope for improved treatment options for cancer patients.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…